entertainment -WSS

entertainment

author：explore 2025-09-06 02:13:10 - browse：65

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

explore

WSS

What will Novo Nordisk's VC do with its influx of cash?

Adopting new red light myopia treatments may be short

Congress extends some pandemic preparedness programs

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Medicare Advantage plans can’t deny care with AI, CMS warns

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

explore

entertainment

Sign up for Morning Rounds

focus

Moonlake's readout produced a cash windfall. Risks remain

Some top drug companies are starting to take action on climate

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Lawsuit highlights wrinkle for disputes over surprise medical bills

DIEP, the 'gold standard' of breast reconstruction, is under threat

6 solutions to address cancer drug shortages and others

Peter Hotez and the public health issue of online harassment

Some top drug companies are starting to take action on climate

Novavax promises a turnaround & Lilly roils the obesity market

The stability of $0 premiums in Medicare Advantage

leisure time

Top private equity targets in 2023: cardiology, clinical trials, lasers

What will Novo Nordisk's VC do with its influx of cash?

Readout LOUD: Venture capital, Gilead, and more M&A

IVG is promising — but it won’t replace IVF quite yet

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

RSV injection headlines need to be accurate for good uptake

hotspot

explore

explore

entertainment